Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/27/2025

Risankizumab for Moderately to Severely Active Crohn's Disease

Clinical Assessment and Indication

  • The European Crohn's and Colitis Organisation (ECCO) guidelines support the use of risankizumab in patients with moderately to severely active Crohn's disease who have documented symptoms of intermittent diarrhea and abdominal pain, with a recent hospitalization for IV fluids due to an episode of diarrhea and abdominal pain lasting one week, and objective evidence of disease activity 1
  • Patients experiencing ongoing symptoms including intermittent diarrhea and abdominal pain, with elevated stool calprotectin, and confirmatory colonoscopy and pathology, are appropriate candidates for risankizumab therapy 1, 2
  • Biologic-naive patients with ileocolonic, nonfistulizing, stricturing Crohn's disease without perianal involvement, are suitable for initiation of biologic therapy with risankizumab 1, 3

Evidence Supporting Efficity

  • The ECCO guidelines strongly recommend risankizumab as both induction and maintenance therapy in moderate-to-severe Crohn's disease (strong recommendation, high-quality evidence) 1, 4
  • Endoscopic remission rates were significantly higher with risankizumab (30-39%) compared to placebo (13%) at week 52 2

Safety Considerations

  • Risankizumab has demonstrated a favorable safety profile consistent with its mechanism of action as a selective IL-23 inhibitor 2, 5

Medical Necessity Determination

  • The American Gastroenterological Association recommends that patients with moderately to severely active Crohn's disease, who meet criteria based on symptoms, hospitalization history, and objective evidence of inflammation, are eligible for risankizumab therapy 1, 5
  • The medication is being prescribed by a gastroenterologist, meeting the specialty requirement, and the patient is not using any other biologic drug or targeted synthetic drug concomitantly 1, 4

Risankizumab Therapy for Crohn's Disease

Clinical Assessment and Disease Severity

  • Objective evidence of inflammation is present with significantly elevated inflammatory markers, well above the threshold that indicates active disease, in patients with Crohn's disease 6
  • Endoscopic findings show severe inflammation in the ileum and aphthous lesions in the colon/rectum, confirming active Crohn's disease 7

Disease Management and Outcomes

  • Early intervention with effective therapy like risankizumab is associated with better long-term outcomes in Crohn's disease, including reduced risk of complications and surgery 8

Medical Necessity Assessment for Risankizumab in Crohn's Disease

Guideline-Based Indications

  • The ECCO 2024 guidelines provide a strong recommendation for risankizumab as both induction and maintenance therapy in moderate-to-severe Crohn's disease (strong recommendation, high-quality evidence) 9
  • The Canadian Association of Gastroenterology guidelines support advanced biologic therapy for patients who have failed conventional treatments and prior anti-TNF therapy 10, 11

Standard of Care Assessment

  • The ECCO guidelines support non-anti-TNF biologics like risankizumab in patients who have failed anti-TNF therapy 9
  • This patient represents an appropriate candidate for risankizumab given prior anti-TNF exposure (Humira) 9

Medical Necessity Determination for Skyrizi (Risankizumab) in Crohn's Disease

Rationale for Medical Necessity

  • The European Crohn's and Colitis Organisation guidelines strongly recommend risankizumab as both induction and maintenance therapy in moderate-to-severe Crohn's disease, with strong recommendation and high-quality evidence 12

Addressing the Insufficient Clinical Information Concerns

  • Objective markers of inflammation, such as C-reactive protein or fecal calprotectin levels, should be documented to confirm active disease, as recommended by Gut in 2019 12
  • Documentation of treatment failure with prior anti-TNF therapy, including explicit statement from the treating gastroenterologist regarding inadequate response, loss of response, or intolerance to infliximab/avsola, is necessary, as supported by Gut in 2019 12

Medical Necessity and Standard of Care Assessment for Risankizumab in Crohn's Disease

Patient Eligibility and Guideline Support

  • The European Crohn's and Colitis Organisation (ECCO) 2024 guidelines provide a strong recommendation for risankizumab as both induction and maintenance therapy in moderate-to-severe Crohn's disease, with high-quality evidence, for patients with moderately to severely active disease and prior biologic failure 13
  • The British Society of Gastroenterology 2025 guidelines support advanced therapy, such as biologics, for patients with moderate to severe disease activity, particularly when there is evidence of ongoing inflammation, which is relevant for this patient's treatment plan 14

Standard of Care and Dosing Schedule

  • The FDA-approved induction regimen for Crohn's disease is 600 mg IV at weeks 0, 4, and 8, which is considered standard of care and supported by evidence from the ADVANCE and MOTIVATE phase 3 induction trials 13
  • Vedolizumab for Crohn's disease uses a 0, 2, 6 week induction schedule, and ustekinumab uses a single IV dose followed by subcutaneous maintenance starting at week 8, highlighting the importance of using the specific approved dosing schedule for each biologic 15, 16

REFERENCES